<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025075</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-50706</org_study_id>
    <nct_id>NCT02025075</nct_id>
  </id_info>
  <brief_title>Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.</brief_title>
  <official_title>A Prospective, Double-blind, Randomized, Crossover Design Study to Compare the Hemodynamic and Respiratory Variations During Laparoscopic Surgery in Patients With and Without Deep Neuromuscular Blockade.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to investigate the effect of depth of neuromuscular block (NMB) on
      global and regional (dependent versus nondependent) respiratory mechanics during laparoscopic
      surgery. Furthermore, we will investigate if the level of NMB influences intraoperative
      hemodynamic and cerebral oxygenation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional Change in Air Content (Delta Z, %)</measure>
    <time_frame>BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum</time_frame>
    <description>We will measure continuous respiratory flows and pressures in the intraoperative period to assess continuously the compliance and resistance of the respiratory system (T1 to T5). In addition, we will use an esophageal balloon to assess esophageal pressures and partition the global mechanical properties of the respiratory system, into their lung and chest wall components (T1 to T5). Regional lung aeration will be assessed for quantification of intraoperative lung recruitment using Electrical Impedance Tomography (EIT) (T0 to T6). Percent change was calculated using electrical impedance measurements obtained at time T0 as reference.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection Fraction (%)</measure>
    <time_frame>BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum</time_frame>
    <description>To assess cardiac performance, transthoracic echocardiography will be used. Ejection fraction was measured as fractional shortening (FS). FS is the fraction of any diastolic dimension that is lost in systole. FS = 100*(LVEDD - LVESD) / LVEDD, LVEDD = LV end-diastolic dimension (mm); LVESD = LV end-systolic dimension (mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral Oximetry (%)</measure>
    <time_frame>BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum</time_frame>
    <description>Regional cerebral oxygenation will be assessed continuously during the intraoperative period using NIRS technology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>Postoperative Day 1</time_frame>
    <description>The patient will be inquired about pain with a visual analogue scale (VAS). Pain will be evaluated as incisional pain using VAS (0 = no pain; 100 = worst possible pain).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Intraoperative Complications</condition>
  <condition>Postoperative Complications</condition>
  <condition>Laparoscopy</condition>
  <condition>Surgical Complications From General Anesthesia</condition>
  <condition>Ventilator-Induced Lung Injury</condition>
  <arm_group>
    <arm_group_label>Deep Neuromuscular Block (NMB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Neuromuscular block (NMB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
    <arm_group_label>Deep Neuromuscular Block (NMB)</arm_group_label>
    <arm_group_label>Moderate Neuromuscular block (NMB)</arm_group_label>
    <other_name>Zemuron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Elective patients scheduled to undergo laparoscopic surgery with expected duration &gt;
             2h

          -  Physical status ASA I - III

        Exclusion Criteria:

          -  Pregnancy

          -  Severe cardiac disease (NYHA class III or IV, acute coronary syndrome, or persistent
             ventricular tachyarrhythmia)

          -  Previous lung surgery

          -  History of severe chronic obstructive pulmonary disease

          -  Gastro-esophageal pathology (including but not limited to recent gastric or esophageal
             surgery including bypass/banding, history of esophageal varices, known anatomical
             gastric or esophageal defects such as strictures, hernias or fistulas)

          -  Mechanical ventilation within the last 30 days

          -  Neuromuscular disease

          -  Consented for another interventional study or refusal to participate in the present
             study

          -  Hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular
             blocking agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos Vidal Melo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Joris J, Cigarini I, Legrand M, Jacquet N, De Groote D, Franchimont P, Lamy M. Metabolic and respiratory changes after cholecystectomy performed via laparotomy or laparoscopy. Br J Anaesth. 1992 Oct;69(4):341-5.</citation>
    <PMID>1419439</PMID>
  </reference>
  <reference>
    <citation>Ivankovich AD, Miletich DJ, Albrecht RF, Heyman HJ, Bonnet RF. Cardiovascular effects of intraperitoneal insufflation with carbon dioxide and nitrous oxide in the dog. Anesthesiology. 1975 Mar;42(3):281-7.</citation>
    <PMID>123134</PMID>
  </reference>
  <reference>
    <citation>Dexter SP, Vucevic M, Gibson J, McMahon MJ. Hemodynamic consequences of high- and low-pressure capnoperitoneum during laparoscopic cholecystectomy. Surg Endosc. 1999 Apr;13(4):376-81.</citation>
    <PMID>10094751</PMID>
  </reference>
  <reference>
    <citation>Karsten J, Heinze H, Meier T. Impact of PEEP during laparoscopic surgery on early postoperative ventilation distribution visualized by electrical impedance tomography. Minerva Anestesiol. 2014 Feb;80(2):158-66. Epub 2013 Jul 23.</citation>
    <PMID>23877309</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <results_first_submitted>March 9, 2017</results_first_submitted>
  <results_first_submitted_qc>April 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Marcos Vidal Melo</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>Tomography</keyword>
  <keyword>Oximetry</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Ventilator-Induced Lung Injury</mesh_term>
    <mesh_term>Intraoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Deep Neuromuscular Block (NMB)</title>
          <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
        </group>
        <group group_id="P2">
          <title>Moderate Neuromuscular Block (NMB)</title>
          <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Deep Neuromuscular Block (NMB)</title>
          <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
        </group>
        <group group_id="B2">
          <title>Moderate Neuromuscular Block (NMB)</title>
          <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="11.9"/>
                    <measurement group_id="B2" value="60.7" spread="9.6"/>
                    <measurement group_id="B3" value="58.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="8.1"/>
                    <measurement group_id="B2" value="28.0" spread="4.5"/>
                    <measurement group_id="B3" value="28.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Physical Status Classification</title>
          <description>ASA I A normal healthy patient ASA II A patient with mild systemic disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Regional Change in Air Content (Delta Z, %)</title>
        <description>We will measure continuous respiratory flows and pressures in the intraoperative period to assess continuously the compliance and resistance of the respiratory system (T1 to T5). In addition, we will use an esophageal balloon to assess esophageal pressures and partition the global mechanical properties of the respiratory system, into their lung and chest wall components (T1 to T5). Regional lung aeration will be assessed for quantification of intraoperative lung recruitment using Electrical Impedance Tomography (EIT) (T0 to T6). Percent change was calculated using electrical impedance measurements obtained at time T0 as reference.</description>
        <time_frame>BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O2">
            <title>Deep Neuromuscular Block (NMB): MODERATE of of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): MODERATE (TOF1) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O3">
            <title>Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O4">
            <title>Moderate Neuromuscular Block (NMB): MOD(1st) of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): MODERATE (1st TOF1) of TOF1-Deep-TOF1 group</description>
          </group>
          <group group_id="O5">
            <title>Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF1 group</description>
          </group>
          <group group_id="O6">
            <title>Moderate Neuromuscular Block (NMB): MOD(2nd) of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): MODERATE (2nd TOF1) of TOF1-Deep-TOF1 group</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Change in Air Content (Delta Z, %)</title>
          <description>We will measure continuous respiratory flows and pressures in the intraoperative period to assess continuously the compliance and resistance of the respiratory system (T1 to T5). In addition, we will use an esophageal balloon to assess esophageal pressures and partition the global mechanical properties of the respiratory system, into their lung and chest wall components (T1 to T5). Regional lung aeration will be assessed for quantification of intraoperative lung recruitment using Electrical Impedance Tomography (EIT) (T0 to T6). Percent change was calculated using electrical impedance measurements obtained at time T0 as reference.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="51.6"/>
                    <measurement group_id="O2" value="29.0" spread="43.0"/>
                    <measurement group_id="O3" value="43.3" spread="39.9"/>
                    <measurement group_id="O4" value="-14.0" spread="40.2"/>
                    <measurement group_id="O5" value="19.4" spread="41.2"/>
                    <measurement group_id="O6" value="29.8" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ejection Fraction (%)</title>
        <description>To assess cardiac performance, transthoracic echocardiography will be used. Ejection fraction was measured as fractional shortening (FS). FS is the fraction of any diastolic dimension that is lost in systole. FS = 100*(LVEDD - LVESD) / LVEDD, LVEDD = LV end-diastolic dimension (mm); LVESD = LV end-systolic dimension (mm).</description>
        <time_frame>BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O2">
            <title>Deep Neuromuscular Block (NMB): MODERATE of of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): MODERATE (TOF1) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O3">
            <title>Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O4">
            <title>Moderate Neuromuscular Block (NMB): MOD(1st) of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): MODERATE (1st TOF1) of TOF1-Deep-TOF1 group</description>
          </group>
          <group group_id="O5">
            <title>Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF1 group</description>
          </group>
          <group group_id="O6">
            <title>Moderate Neuromuscular Block (NMB): MOD(2nd) of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): MODERATE (2nd TOF1) of TOF1-Deep-TOF1 group</description>
          </group>
        </group_list>
        <measure>
          <title>Ejection Fraction (%)</title>
          <description>To assess cardiac performance, transthoracic echocardiography will be used. Ejection fraction was measured as fractional shortening (FS). FS is the fraction of any diastolic dimension that is lost in systole. FS = 100*(LVEDD - LVESD) / LVEDD, LVEDD = LV end-diastolic dimension (mm); LVESD = LV end-systolic dimension (mm).</description>
          <units>% fractional shortening</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="5"/>
                    <measurement group_id="O2" value="34" spread="5"/>
                    <measurement group_id="O3" value="35" spread="4"/>
                    <measurement group_id="O4" value="35" spread="5"/>
                    <measurement group_id="O5" value="36" spread="2"/>
                    <measurement group_id="O6" value="37" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cerebral Oximetry (%)</title>
        <description>Regional cerebral oxygenation will be assessed continuously during the intraoperative period using NIRS technology.</description>
        <time_frame>BL; During pneumoperitoneum; Stage w/2 depths neuromuscular blockade targeted - TOF1 and Deep: 1-2 twitches in post-tetanic count (50-Hz tetanus followed by three-second pause and 15 1-Hz stimuli); and immediately after release of pneumoperitoneum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): Deep (1st) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O2">
            <title>Deep Neuromuscular Block (NMB): MODERATE of of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): MODERATE (TOF1) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O3">
            <title>Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep</title>
            <description>Deep Neuromuscular Block (NMB): Deep (2nd) of Deep-TOF1-Deep group</description>
          </group>
          <group group_id="O4">
            <title>Moderate Neuromuscular Block (NMB): MOD(1st) of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): MODERATE (1st TOF1) of TOF1-Deep-TOF1 group</description>
          </group>
          <group group_id="O5">
            <title>Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): Deep of TOF1-Deep-TOF1 group</description>
          </group>
          <group group_id="O6">
            <title>Moderate Neuromuscular Block (NMB): MOD(2nd) of TOF1-Deep-TOF1</title>
            <description>Moderate Neuromuscular Block (NMB): MODERATE (2nd TOF1) of TOF1-Deep-TOF1 group</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Oximetry (%)</title>
          <description>Regional cerebral oxygenation will be assessed continuously during the intraoperative period using NIRS technology.</description>
          <units>percent cerebral saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="6"/>
                    <measurement group_id="O2" value="73" spread="5"/>
                    <measurement group_id="O3" value="74" spread="6"/>
                    <measurement group_id="O4" value="75" spread="6"/>
                    <measurement group_id="O5" value="75" spread="6"/>
                    <measurement group_id="O6" value="75" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain</title>
        <description>The patient will be inquired about pain with a visual analogue scale (VAS). Pain will be evaluated as incisional pain using VAS (0 = no pain; 100 = worst possible pain).</description>
        <time_frame>Postoperative Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deep Neuromuscular Block (NMB)</title>
            <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
          </group>
          <group group_id="O2">
            <title>Moderate Neuromuscular Block (NMB)</title>
            <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain</title>
          <description>The patient will be inquired about pain with a visual analogue scale (VAS). Pain will be evaluated as incisional pain using VAS (0 = no pain; 100 = worst possible pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.0"/>
                    <measurement group_id="O2" value="3.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Deep Neuromuscular Block (NMB)</title>
          <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
        </group>
        <group group_id="E2">
          <title>Moderate Neuromuscular Block (NMB)</title>
          <description>Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
Rocuronium: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcos Vidal Melo, MD, PhD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-8980</phone>
      <email>VidalMelo.Marcos@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

